This report The World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not estimates the market for molecular diagnostics and provides a realistic look at the role of molecular testing and its future in various market segments. Kalorama Information's lead diagnostics analyst Shara Rosen, R.T., MBA, also reviews the competitors in the market and their latest moves.
There have been many predictions made about a molecular revolution in diagnostics. Indeed some are now taking place, while other predictions have not turned out to be true. How can companies sort out what is effective and what is not in this market?
World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not provides the insights needed to gain a clear picture of the industry, helping you to make better strategic decisions. It not only contains current market data for business planning but also goes beyond the numbers to fully assess what is going on in the market. For over a decade, Shara Rosen has reviewed the molecular diagnostics market. A lot has changed, and a lot has stayed the same. There is intense competition but also opportunities for entrants in some areas.
What are the important developments in the market? Who are the small innovators in this industry and how are the big players reacting to them? Which developments are "hot" and which trends have not caught on? In this report, Rosen provides answers to these questions.
As we enter the second decade of the 21st century the investments in molecular biology, in bioinformatics, in disease management research and the unraveling of the human genome are bearing fruit. Almost every day the discovery of new molecular markers for cancer, cardiac disease, diabetes, arthritis, neurological diseases and psychiatric conditions are being announced.
Far from being a cheerleader of what is clearly a growth market, The World Market for Molecular Diagnostics -Potential and Reality, What's Hot and What's Not provides a detailed examination of molecular testing today. Among the data points the report provides are the following:
This renewed interest in IVD in general and more particularly in molecular diagnostics has lead to the commercialization of a number of technological tools that make more sensitive and specific tests possible. Some of these technological innovations include: cost-effective, multiplexed testing platforms coupled with high-powered software capabilities. In addition analyses using saliva, urine, and blood instead of biopsied tissue make for more patient-friendly test systems.
Kalorama provides profiles of over 110 companies participating in the market. All of these companies have different strategies and compete in different areas, and Kalorama acknowledges this by separating the companies in a triage system based on where they stand in the molecular in vitro diagnostics market.
Molecular diagnostics is a complicated market that requires a thorough analysis to understand. Many reports make bold predictions which later are proved incorrect by market events. In this report, Kalorama Information provides revenues and market forecasts, but also looks deeply at some of the trends in the market and what might impact results in the future. The report summarizes what is working and what is not working in the past few years. Shara Rosen, RT, MBA, looks at the 'Hot' Trends and the 'Lukewarm' Trends, including:
Market size and forecasts in the report are for manufacturer's revenues. Secondary and primary resources, including: trade publications, annual report and interviews with key executives in molecular diagnostics were used for this study.
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
Since 2000, sales of molecular tests have increased five-fold, and the number of companies and tests on the market has literally exploded. According to healthcare market research publisher Kalorama Information in its newly updated title, World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not, some 350 companies are actively involved in molecular diagnostics today, and although growth in the market for molecular assays has been very strong, it hasn't been quite as robust as anticipated in 2007.
The world market for molecular tests grew its share of the IVD market from 2% in 1995 to about 10% in 2009. This is quite an achievement and stands as a testament to the spirit of innovation in the IVD industry. But recently, growth was somewhat slower than originally anticipated due in part to the economic recession, a lack of trained lab technicians, and increasing cost pressures. Kalorama forecasts growth of about 11% annually through 2015. That's healthy growth, according to the report, but a little shy of the boldest predictions in the media and among industry analysts of twenty percent or more.
"Molecular diagnostics--one of the fastest growing segments in diagnostics--is becoming the dominant platform in clinical medicine and it has made rapid and timely information about infectious diseases and bacterial infections a reality," notes Shara Rosen, R.T., MBA, Kalorama Information's senior diagnostics analyst and author of the report. "New molecular tests are being launched all the time, many of which are CE Marked and FDA-cleared."
The primary growth drivers in the molecular diagnostics market overall, are the continued discovery of genetic markers with proven clinical utility, the increasing adoption of genetic based diagnostic tests, and the expansion of reimbursement programs to include a greater number of approved diagnostic tests. The most attractive growth areas are molecular tests for women's health, infectious diseases, organ transplant testing and oncology. Advances in cancer therapies and the allure of personalized medicine provide another compelling argument for growth in the market for molecular tests and technologies.
However, the contribution that these tests can make to patient outcomes faces some barriers including reimbursement programs that still lag behind the speed of innovation, competition from test services in some segments, complexity, and limited quality control products and programs, according to Kalorama.
"One of the major challenges facing molecular diagnostics is getting stakeholders--including payers, physicians, researchers and regulators--to work together to close the gap between research and clinical applicability," notes Rosen.
World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not, separates fast-growth areas of molecular diagnostics from those that are slower-paced. It estimates the market and provides a realistic look at its role and its future in various market segments. The report discusses tests and technologies that are currently available and those in the pipeline. It also reviews the competitors in the market and their latest moves.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook